Ethinylestradiol/cyproterone acetate in polycystic ovary syndrome: lipid and carbohydrate changes.

@article{Villaseca2004EthinylestradiolcyproteroneAI,
  title={Ethinylestradiol/cyproterone acetate in polycystic ovary syndrome: lipid and carbohydrate changes.},
  author={P Villaseca and Paola Andrea Hormaza and I C{\'a}rdenas and Eveline Oestreicher and Eugenio Arteaga},
  journal={The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception},
  year={2004},
  volume={9 3},
  pages={
          155-65
        }
}
OBJECTIVE Ethinylestradiol (EE) combined with the antiandrogenic progestin cyproterone acetate (CPA) is a possible treatment in polycystic ovary syndrome (PCOS). We investigated the impact of EE/CPA on lipid and carbohydrate metabolism in women with PCOS,who were otherwise healthy. METHOD The 31 women were separated into two groups paired by body mass index (BMI): Group A (control, n = 15) were cycled with 10 mg medroxyprogesterone acetate (MPA) x 10 days (Provera, Pharmacia & Upjohn) every… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-9 OF 9 CITATIONS

The effects of old, new and emerging medicines on metabolic aberrations in PCOS.

  • Therapeutic advances in endocrinology and metabolism
  • 2012
VIEW 5 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Increased thrombin-activatable fibrinolysis inhibitor antigen levels as a clue for prothrombotic state in polycystic ovary syndrome.

  • Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology
  • 2008
VIEW 1 EXCERPT
CITES BACKGROUND